Mitapivat (AG-348) hydrochloride is an orally active and selective allosteric activator of pyruvate kinase R (PK-R). It enhances the PK-R-catalyzed conversion of phosphoenolpyruvate to pyruvate, thereby promoting the glycolysis pathway, increasing ATP production in red blood cells, and decreasing 2,3-diphosphoglycerate (2,3-DPG) levels. Mitapivat hydrochloride is being investigated for potential use in the study of pyruvate kinase deficiency and other anemia-related disorders.